IL17A and amyotrophic lateral sclerosis: Our results show a higher expression of IL-17A but lower expression of IL-10 in patients than controls, suggesting that the activation of regulatory T pathways is suppressed in patients, further suggesting a higher vulnerability of ALS patients to IL-17A-mediated damage.